Rhodes Jason P sold DYN
July 7, 2026 · Form 4 insider transaction
Rhodes Jason P sold 49,193 shares of Dyne Therapeutics, Inc. at $23.17 per share, a transaction worth $1.14M. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 1 day after the transaction.
Footnotes
Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026.; The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.4572 to $23.4553 inclusive.; The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any.